On 2 June 2015, Mylan, Par Pharmaceuticals, Sandoz and Teva Pharmaceuticals (Teva) launched generic versions of Intuniv (guanfacine) extended-release tablets in doses of 1, 2, 3 and 4 mg strengths following approval by the US Food and Drug Administration (FDA) of their abbreviated new drug applications (ANDAs). Teva now has eight generic ADHD products.

Although Shire’s patent for Intuniv only expires in September 2015, the company made an agreement with generics maker Actavis in April 2013. The deal allowed Actavis to launch a generic version of the drug in December 2014, with 180 days of marketing exclusivity. Now that the exclusivity period is over, other generics makers can enter the US market.

Guanfacine is a non-stimulant medication for the treatment of ADHD that can be used alone, or as an add-on to stimulant medications.

ADHD is the most common neurobehavioural disorder diagnosed in children in the US. ADHD affects one in 10 US children and half of these children are diagnosed by the age of six.

Intuniv had total market sales of approximately US$800 million in the US, according to IMS data as of March 2015.

Related articles
FDA withdraws automatic substitution of two methylphenidate generics

Mylan latest to recall blood pressure generic

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.